Therapy of multiple sclerosis
Disease-Modifying Therapies
Four partially disease-modifying therapies (DMP) for the initial management of MS are available in the united States : IFNb-1a (Avonex), IFNb-1a (Rebif) ,IFNb-1b (Betaseron) ,and glatiramer acetate (Compaxone). Mitoxantron (Novantron) was approved in the United States for the treatment of worsening forms of RR-MS ,PM-MS , and SP-MS. A sixth novel agent, Natalizumab (Tysabri) ,was reapproved for use in the United States for patients